AngioDynamics (ANGO) Tops Q2 EPS by 5c, Revenues Beat; Offers FY19 EPS/Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
AngioDynamics Reports Fiscal 2019 Second Quarter Financial Results
January 4, 2019 7:00 AM ESTFiscal 2019 Second Quarter Highlights
Net sales of $91.5 million, an increase of 5.5% year over year Gross margin expanded 440 basis points year over year to 53.7% GAAP EPS of $0.06 per share; adjusted EPS of $0.22 per share Cash provided by operations of $13.0 million; capital expenditures of $0.7 million Announced the acquisition of RadiaDyne and its proprietary OARtrac® radiation dose monitoring platform to build the Companys continuum of care within the oncology spaceLATHAM,... More
